650 East Kendall Street
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com.
Stock Symbol: TAK
Science is the foundation for everything we do at Takeda. We connect to our 240- year history and our strong values through our pursuit of life-transforming science where we embrace a culture of collaboration, pursue modalities based on validated targets, evaluate real-world impact and generate data that may enable accelerated development and regulatory pathways.
1449 articles about Takeda
Takeda Pharmaceuticals North America, Inc.'s Proton Pump Inhibitor DEXILANT(TM) (dexlansoprazole) Now Available in U.S. Pharmacies
Dimerix Bioscience and Takeda Pharmaceutical Co. Ltd. Sign Agreement to Use GPCR-HIT Platform in Discovery Program
XOMA (US) LLC Receives $1 Million Milestone Payment From Takeda Pharmaceutical Co. Ltd.
Metabolex, Inc. Initiates Research Collaboration with Takeda Pharmaceutical Co. Ltd.
Takeda Pharmaceutical Co. Ltd. Backs British Amputee Football Team for 2010 World Cup
Seattle Genetics, Inc., Takeda Pharmaceutical Co. Ltd. and Millennium: The Takeda Oncology Company Announce Initiation of Phase III AETHERA Trial of Brentuximab Vedotin (SGN-35) for Post-Transplant Hodgkin Lymphoma
AMAG Pharmaceuticals, Inc. Enters into Anemia Drug Licensing Deal with Takeda Pharmaceutical Co. Ltd.; AMAG to Get $60 Million Upfront, Eligible for $220 Million in Milestone Payments
Alnylam Pharmaceuticals Completes Key Technology Transfer Objectives in its Takeda Pharmaceutical Co. Ltd. Alliance and Earns $20 Million Payment
U.S. FDA Says Takeda Pharmaceutical Co. Ltd. Sleep Drug Promotion Misleads
Takeda Pharmaceutical Co. Ltd. Drops Application for Diabetes Drug in Europe
Watson Pharmaceuticals, Inc., Takeda Pharmaceutical Co. Ltd. Resolve Actos Patent Litigation
Affymax, Inc. Receives $5 Million Milestone Payment from Takeda Pharmaceutical Co. Ltd. on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Takeda Pharmaceuticals North America, Inc.'s KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion
CellCentric Ltd. Licenses Novel Epigenetic Discovery Program to Takeda Pharmaceutical Co. Ltd. (JOBS); Deal Could be Worth Excess of $200 Million
Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Co. Ltd. Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity Phase 2 Extension Study Demonstrated Sustained Weight Loss
NextGen Sciences Ltd. to Develop and Validate Protein Biomarker Assays for Takeda Pharmaceutical Co. Ltd.
FDAAdvisoryCommittee.com Approves Addition of Sustained Overall Survival Benefit to Label for Takeda's (JOBS) VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Pfizer Inc. (JOBS), Takeda Pharmaceutical Co. Ltd. (JOBS) to Promote Diabetes Drug in China
Japan's Takeda Pharmaceutical Co. Ltd. (JOBS) Hires India Head, to Decide on Entry
Takeda Pharmaceutical Co. Ltd. (JOBS) Eyeing M&A for Generics in Emerging Markets